Biodexa Pharmaceuticals
BDRX | NASDAQ
$2.82
-$0.61 (-17.78%)
Nov 2, 2026, 3:50 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 381K | 699K | 578K | 343K |
Cost of Revenue | 184.86K | 5.44M | 4.07M | 5.11M | 4.65M | 6.07M |
Gross Profit | -184.86K | -5.44M | -3.69M | -4.41M | -4.08M | -5.73M |
Operating Income | -8.27M | -9.2M | -8.01M | -8.93M | -7M | -23.04M |
Interest Income | 87.05K | 2K | 83K | 29K | n/a | 1K |
Pretax Income | -6.35M | -5.98M | -7.49M | -8.49M | -6.11M | -23.47M |
Net Income | -6.24M | -5.73M | -7.08M | -7.66M | -5.46M | -22.19M |
Selling & General & Admin | 4.84M | 3.79M | 4.34M | 4.54M | 2.95M | 4.96M |
Research & Development | 3.73M | 5.44M | 4.07M | 5.11M | 4.65M | 16.15M |
Other Expenses | -482.54K | -5.47M | -4.08M | -5.13M | -4.68M | -3.79M |
Operating Expenses | 8.08M | 3.76M | 4.33M | 4.52M | 2.92M | 17.32M |
Interest Expense | 68.47K | n/a | 41K | 53K | 44K | 34K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 8.27M | 9.2M | 8.4M | 9.63M | 7.58M | 23.38M |
Income Tax Expense | -102.7K | -250K | -406K | -832K | -646K | -1.28M |
Shares Outstanding (Basic) | 27.43M | 2.48M | 157.93K | 2.47K | 2.01K | 1.07K |
Shares Outstanding (Diluted) | 27.43M | 2.48M | 157.93K | 2.47K | 2.01K | 1.07K |
EPS (Basic) | -0.32 | -2.96 | -55.71 | -3.82K | -3.73K | -26.57K |
EPS (Diluted) | -0.32 | -2.96 | -55.71 | -3.82K | -3.73K | -26.57K |
EBITDA | -8.08M | -8.95M | -7.16M | -8.09M | -5.66M | -22.22M |
EBIT | -8.27M | -9.2M | -7.44M | -8.44M | -6.06M | -23.44M |
Depreciation & Amortization | 184.86K | 254K | 283K | 343K | 403K | 1.22M |
Add to Watchlist
Select watchlists to add or remove BDRX